|
1
|
Salah S, Ahmad R, Sultan I, Yaser S and
Shehadeh A: Osteosarcoma with metastasis at initial diagnosis:
Current outcomes and prognostic factors in the context of a
comprehensive cancer center. Mol Clin Oncol. 2:811–816.
2014.PubMed/NCBI
|
|
2
|
Lewis VO: What's new in musculoskeletal
oncology. J Bone Joint Surg Am. 91:1546–1556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Iwamoto Y, Tanaka K, Isu K, Kawai A,
Tatezaki S, Ishii T, Kushida K, Beppu Y, Usui M, Tateishi A, et al:
Multiinstitutional phase II study of neoadjuvant chemotherapy for
osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop
Sci. 14:397–404. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cho Y, Jung GH, Chung SH, Kim JY, Choi Y
and Kim JD: Long-term survivals of stage IIb osteosarcoma: A
20-year experience in a single institution. Clin Orthop Surg.
3:48–54. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bölling T, Schuller P, Distelmaier B,
Schuck A, Ernst I, Gosheger G, Winkelmann W, Dirksen U, Jürgens H,
Kronholz HL, et al: Perioperative high-dose rate brachytherapy
using a bendy applicator (flab): Treatment results of 74 patients.
Anticancer Res. 28:3885–3890. 2008.PubMed/NCBI
|
|
6
|
Lourda M, Trougakos IP and Gonos ES:
Development of resistance to chemotherapeutic drugs in human
osteosarcoma cell lines largely depends on up-regulation of
Clusterin/Apolipoprotein J. Int J Cancer. 120:611–622. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schwartz CL, Gorlick R, Teot L, Krailo M,
Chen Z, Goorin A, Grier HE, Bernstein ML and Meyers P: Children's
Oncology Group: Multiple drug resistance in osteogenic sarcoma:
INT0133 from the Children's Oncology Group. J Clin Oncol.
25:2057–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dolfini D, Gatta R and Mantovani R: NF-Y
and the transcriptional activation of CCAAT promoters. Crit Rev
Biochem Mol Biol. 47:29–49. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mojsin M, Topalovic V, Vicentic J
Marjanovic and Stevanovic M: Transcription factor NF-Y inhibits
cell growth and decreases SOX2 expression in human embryonal
carcinoma cell line NT2/D1. Biochemistry (Mosc). 80:202–207. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Garipov A, Li H, Bitler BG, Thapa RJ,
Balachandran S and Zhang R: NF-YA underlies EZH2 upregulation and
is essential for proliferation of human epithelial ovarian cancer
cells. Mol Cancer Res. 11:360–369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bungartz G, Land H, Scadden DT and Emerson
SG: NF-Y is necessary for hematopoietic stem cell proliferation and
survival. Blood. 119:1380–1389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang HT, Zhang D, Zha ZG and Hu CD:
Transcriptional activation of PRMT5 by NF-Y is required for cell
growth and negatively regulated by the PKC/c-Fos signaling in
prostate cancer cells. Biochim Biophys Acta. 1839:1330–1340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma H, Yue X, Gao L, Liang X, Yan W, Zhang
Z, Shan H, Zhang H, Spear BT and Ma C: ZHX2 enhances the
cytotoxicity of chemotherapeutic drugs in liver tumor cells by
repressing MDR1 via interfering with NF-YA. Oncotarget.
6:1049–1063. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi Z, Chiang CI, Labhart P, Zhao Y, Yang
J, Mistretta TA, Henning SJ, Maity SN and Mori-Akiyama Y:
Context-specific role of SOX9 in NF-Y mediated gene regulation in
colorectal cancer cells. Nucleic Acids Res. 43:6257–6269. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu ZL, Wang G, Peng AF, Luo QF, Zhou Y
and Huang SH: Fatty acid synthase expression in osteosarcoma and
its correlation with pulmonary metastasis. Oncol Lett. 4:878–882.
2012.PubMed/NCBI
|
|
18
|
Liu ZL, Mao JH, Peng AF, Yin QS, Zhou Y,
Long XH and Huang SH: Inhibition of fatty acid synthase suppresses
osteosarcoma cell invasion and migration via downregulation of the
PI3K/Akt signaling pathway in vitro. Mol Med Rep. 7:608–612.
2013.PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hackenberg D, Wu Y, Voigt A, Adams R,
Schramm P and Grimm B: Studies on differential nuclear
translocation mechanism and assembly of the three subunits of the
Arabidopsis thaliana transcription factor NF-Y. Mol Plant.
5:876–888. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ying S, Dunnebier T, Si J and Hamann U:
Estrogen receptor alpha and nuclear factor Y coordinately regulate
the transcription of the SUMO-conjugating UBC9 gene in MCF-7 breast
cancer cells. PLoS One. 8:e756952013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Belluti S, Basile V, Benatti P, Ferrari E,
Marverti G and Imbriano C: Concurrent inhibition of enzymatic
activity and NF-Y-mediated transcription of Topoisomerase-IIα by
bis-DemethoxyCurcumin in cancer cells. Cell Death Dis. 4:e7562013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lützner N, De-Castro Arce J and Rösl F:
Gene expression of the tumour suppressor LKB1 is mediated by Sp1,
NF-Y and FOXO transcription factors. PLoS One. 7:e325902012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamanaka K, Mizuarai S, Eguchi T, Itadani
H, Hirai H and Kotani H: Expression levels of NF-Y target genes
changed by CDKN1B correlate with clinical prognosis in multiple
cancers. Genomics. 94:219–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uemoto Y, Abe T, Tameoka N, Hasebe H,
Inoue K, Nakajima H, Shoji N, Kobayashi M and Kobayashi E:
Whole-genome association study for fatty acid composition of oleic
acid in Japanese Black cattle. Anim Genet. 42:141–148. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bian Y, Yu Y, Wang S and Li L:
Up-regulation of fatty acid synthase induced by EGFR/ERK activation
promotes tumor growth in pancreatic cancer. Biochem Biophys Res
Commun. 463:612–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bauerschlag DO, Maass N, Leonhardt P,
Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba
R, Meinhold-Heerlein I and Bräutigam K: Fatty acid synthase
overexpression: Target for therapy and reversal of chemoresistance
in ovarian cancer. J Transl Med. 13:1462015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grube S, Dunisch P, Freitag D, Klausnitzer
M, Sakr Y, Walter J, Kalff R and Ewald C: Overexpression of fatty
acid synthase in human gliomas correlates with the WHO tumor grade
and inhibition with Orlistat reduces cell viability and triggers
apoptosis. J Neurooncol. 118:277–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agostini M, Almeida LY, Bastos DC, Ortega
RM, Moreira FS, Seguin F, Zecchin KG, Raposo HF, Oliveira HC,
Amoêdo ND, et al: The fatty acid synthase inhibitor orlistat
reduces the growth and metastasis of orthotopic tongue oral
squamous cell carcinomas. Mol Cancer Ther. 13:585–595. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zaytseva YY, Harris JW, Mitov MI, Kim JT,
Butterfield DA, Lee EY, Weiss HL, Gao T and Evers BM: Increased
expression of fatty acid synthase provides a survival advantage to
colorectal cancer cells via upregulation of cellular respiration.
Oncotarget. 6:18891–18904. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu H, Fu J, Ha SW, Ju D, Zheng J, Li L and
Xie Y: The CCAAT box-binding transcription factor NF-Y regulates
basal expression of human proteasome genes. Biochim Biophys Acta.
1823:818–825. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lu YH, Dallner OS, Birsoy K,
Fayzikhodjaeva G and Friedman JM: Nuclear Factor-Y is an adipogenic
factor that regulates leptin gene expression. Mol Metab. 4:392–405.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hida M, Hamanaka R, Okamoto O, Yamashita
K, Sasaki T, Yoshioka H and Matsuo N: Nuclear factor Y (NF-Y)
regulates the proximal promoter activity of the mouse collagen
α1(XI) gene (Col11a1) in chondrocytes. In Vitro Cell Dev Biol Anim.
50:358–366. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Teran-Garcia M, Adamson AW, Yu G, Rufo C,
Suchankova G, Dreesen TD, Tekle M, Clarke SD and Gettys TW:
Polyunsaturated fatty acid suppression of fatty acid synthase
(FASN): Evidence for dietary modulation of NF-Y binding to the Fasn
promoter by SREBP-1c. Biochem J. 402:591–600. 2007. View Article : Google Scholar : PubMed/NCBI
|
